We have studied the short term regulation of insulin receptors by serially measuring insulin binding to erythrocytes during 5 h of infusions of glucose and insulin. Two infusion protocols were employed: (1) Hyperinsulinemic study. Subjects were infused with insulin (80 mU/min) to induce sustained hyperinsulinemia, while euglycemia was approximated by infusion of glucose (8 mg/kg/min). (2) Hyperglycemic study. Subjects were infused with glucose (7 mg/kg/min) and a small amount of insulin (10 mU/min), while endogenous insulin secretion was inhibited with epinephrine and propranolol. Insulin binding to erythrocyte insulin receptors was measured serially during both of these infusion protocols for 5 h. The results demonstrated no change in insulin binding during the first 3 h of either infusion. However, by 5 h of either infusion, a striking 36% decrease in insulin binding, from 6.3 ± 0.5% to 4.0 ± 0.6%, was observed. Scatchard analysis and average affinity analysis of the binding data demonstrated that this decrease in insulin binding was entirely caused by a decrease in receptor affinity. Insulin binding to circulating monocytes was also measured, and comparable effects were observed. When cells were removed from the in vivo environment at 3 h and were incubated in vitro for a subsequent 2 h, decreased insulin binding developed during the incubation. Thus, this short term regulation of insulin receptor affinity occurred in vivo or in vitro, and cells that were programmed during the first 3 h of the infusion study could develop a decrease in insulin receptor affinity in vitro in the absence of plasma factors. DIABETES 29:132-139, February 1980.
I
nsulin binding to receptors is the first event in insulin action, and this step represents a major control point for insulin's effects in vivo. 1 Insulin binding to receptors is not a fixed biologic process but is subject to modulation by alterations in either receptor number or affinity. 2 " 4 However, changes in insulin receptor number appear to take several days to develop in man 5 " 7 and do not provide an adaptive mechanism for short term (within 24 to 48 h) regulation of insulin binding. Several situations have been reported in which acute (up to 48 h) alterations in insulin binding occur, and these effects are secondary to modulation of receptor affinity. 5 " 9 Recently, we have reported that short term (5 day) high carbohydrate feeding in man lead to a decrease in the binding affinity of adipocyte insulin receptors, whereas long term high carbohydrate ingestion leads to a reduction in adipocyte insulin receptor number. 7 Thus, the short term adaptive response of the insulin receptor appears to be mediated through changes in receptor affinity whereas the long term response requires a change in receptor number. To further explore the mechanisms whereby receptor affinity can be regulated, we have serially assessed the ability of insulin to bind to human erythrocytes during 5 h of glucose and insulin infusions. Subjects. The study group consisted of nine nonobese normal subjects (two men and seven women), whose ages ranged from 26 to 58 yr. The subjects' relative weights ranged from 0.75 to 1.20, with a mean of 0.95. After informed consent was obtained from them, subjects were admitted to the University of Colorado Clinical Research Center. No patient had a history of recent weight change or a history of illness known to affect glucose metabolism. All oral glucose tolerance tests were normal. Diet. The subjects consumed a weight-maintaining liquid diet consisting of 45% carbohydrate, 40% fat, and 15% protein. The daily intake of 35 kcal/kg/day was divided into portions of 1/5, 2/5, and 2/5 served at 8 a.m., 12 noon, and 6 p.m. Daily weights were monitored for all subjects and were constant throughout the study. Each subject was allowed to stabilize on the diet for at least 48 h before any study. Protocol. After 12 h of an overnight fast, blood samples were obtained for measurements of plasma glucose, plasma insulin, and insulin binding to erythrocytes. Each subject was then given an intravenous injection of 5 mg of propranolol, followed in 5 min by an infusion of glucose (7 or 8 mg/kg/min), epinephrine (6 ^g/min), propranolol (0.08 mg/min), and insulin. The insulin was infused at either 10 or 80 mU/min. The solution was infused continuously for 5 h via a Harvard infusion pump (Millis, Mass.) into an antecubital vein. Blood samples were obtained at 3 h and 5 h for determination of plasma glucose, insulin, growth hormone, cortisol, and insulin binding to erythrocytes. These samples were drawn from the opposite arm through a needle kept patent by a slow saline infusion.
MATERIALS AND METHODS

Materials
Under these experimental conditions, endogenous insulin secretion is suppressed by the epinephrine and propranolol, and steady state plasma glucose and insulin levels are reached by 90 min. 10 During one of the two infusion protocols-termed the hyperglycemic infusion-insulin was infused at 10 mU/min to maintain a steady state insulin concentration at, or near, basal levels while it allowed hyperglycemia to occur in response to the glucose infusion (7 mg/kg/min). During the other infusion protocol-termed the hyperinsulinemic infusion-insulin was given at 80 mU/min to achieve hyperinsulinemia while it maintained plasma glucose near basal levels via the administration of glucose (8 mg/kg/min). Studies were performed at least 2 days apart; both infusion protocols were carried out in five of the nine subjects, while only one protocol was given in the other subjects.
CELL PREPARATION AND INSULIN BINDING STUDIES
Erythrocytes. Insulin binding to erythrocytes was measured according to a modification of the method of Gambhir et al. 11~13 Whole blood (10 ml) was drawn into heparinized tubes and centrifuged for 10 min (400 g at 20°). The resulting cell pellet was diluted 1:1 with phosphate-buffered saline and the red cells were fractionated on a Ficoll-Hypaque gradient. After isolating the resultant red cell pellet, the latter two steps were repeated and the cell pellet was diluted 1:2 with a buffer containing 50 mM Hepes, 50 mMTris, 50 mM sodium chloride, 10 mM CaCI, 10 mM MgCI 2 , 5 mM KCI, 10 mM glucose, 2 mM EDTA, and 1%BSA, pH 8.0, 15°. The erythrocyte suspension was centrifuged and the pellet was resuspended in 1 % BSA buffer to yield a final cell concentration of 4.4 x 10 9 /ml. Cell viability was always >98%, as determined by exclusion of trypan blue. Cell counts were performed with a hemacytometer. Insulin-binding studies. [
125 l]insulin was prepared with a specific activity of between 100 and 150 /xCi/^g by the modification of Freychet et al.
14 of the method of Hunter and Greenwood. 15 Insulin binding to receptors was assessed by incubating cells with [ 125 l]insulin (3.3 x 10~1 1 M) and by increasing the concentrations of unlabeled insulin at 15°C for 2.5 h in a total volume of 0.5 ml. At the end of the incubation, duplicate 200 /x\ aliquots were added to prechilled plastic tubes containing 100 /ul of dibutyl phthalate and 100 ^l of the 1 % BSA buffer. The microfuge tubes were centrifuged for 120 s in a Beckman Microfuge, and the radioactivity in the cell pellets was determined. Nonspecific binding was defined as the amount of cell-associated [
125 l]insulin in the presence of a large excess, 10 5 ng/ml, of unlabeled insulin. All data were corrected for this factor and represent specific insulin binding. The amount of insulin specifically bound was normalized to a cell concentration of 3.5 x 10 9 /ml. Monocytes. Isolated monocytes were prepared and insulin-binding studies were performed according to previously described methods. Analytic procedures. Blood to measure glucose and insulin was drawn into test tubes containing EDTA, the plasma quickly separated, and aliquots stored at -20°C until insulin determinations were done. Plasma glucose was measured by the glucose oxidase method in a glucose analyzer (Beckman Instruments, Fullerton, Calif.). Plasma insulin was measured by a two antibody radioimmunoassay according to the method of Desbuquois and Aurbach. 18 Glucose and insulin values are reported as the mean (±SE). Statistical Analysis. All P values were obtained by use of the paired Student's t test. erythrocytes was 6.1 ± 0.4% for the entire study group. Interassay variation was 8% and nonspecific binding averaged 15% of total binding. Plasma glucose and insulin levels during the infusion studies. Two separate 5 h infusion protocols were employed. The first infusion was designed to produce hyperinsulinemia and maintain euglycemia; it will be called the hyperinsulinemic infusion, hereafter. This was accomplished by suppressing endogenous insulin secretion with epinephrine and propranolol so that the resultant steady state plasma insulin levels were essentially a reflection of the infused exogenous insulin (80 mU/min). Euglycemia was approximated by administering glucose at 8 mg/kg/min. Many samples (5) (6) (7) (8) (9) (10) (11) were obtained during the final 2 h of the infusion, and steady state levels were clearly achieved in all subjects. protocol was designed to produce hyperglycemia and to maintain insulin near basal values; it is termed the hyperglycemic infusion. During this protocol, endogenous insulin secretion was suppressed by epinephrine and propranolol, and a small amount of exogenous insulin was infused (10 mU/min) to maintain basal levels. Hyperglycemia was produced by infusing glucose at 7 mg/kg/min. Steady state values were clearly achieved in all subjects, and the coefficient of variation of all values obtained from 180 to 300 min for each of the nine individual studies were 9, 6, 5, 1, 2, 2, 1, 3, and 1 for glucose levels and 15, 9, 6, 14, 7, 14, 6, 7, and 10 for insulin levels. The mean (±SE) glucose values (mg/100 ml) during the steady state were 256 ± 25 at 180 min, 233 ± 31 at 280 min, 228 ± 30 at 285 min, 231 ± 31 at 290 min, 232 ± 29 at 295 min, and 228 ± 28 at 300 min. The mean (±SE) insulin values (^U/ml) during the steady state were 30 ± 7 at 180 min, 28 ± 5 at 280 min, 27 ± 5 at 285 min, 27 ± 5 at 290 min, 30 ± 7 at 295 min, and 31 ± 9 at 300 min. The basal insulin value was 7 ± 2 [A)/rc\\. Thus, substantial hyperglycemia was achieved with a minimal elevation of the insulin level. Three of the eight subjects who received this infusion had 3 h and 5 insulin levels of less than 15 ^ill/ml. The mean (±SE) basal and steady state glucose and insulin values during both infusion protocols are presented in Figure 1 .
RESULTS
Insulin
Insulin-binding studies in vivo.
Cells were prepared for insulin binding studies before and at both 3 h and 5 h of each infusion protocol; the results are presented in Table 1 . As can be seen, no change in insulin binding to erythrocytes occurred after 3 h of either infusion. On the other hand, a highly significant 36% decrease in the ability of cells to specifically bind tracer concentrations of insulin was observed at 5 h. The magnitude of this change was similar with both infusion protocols as was the level of insulin binding under basal conditions. To see if this decrease in insulin binding was due to a change in receptor number or affinity, the complete competition curves were analyzed. The data in Figure 2 demonstrate that, after 5 h of either infusion, insulin binding is decreased at the lower insulin concentrations, but the curves converge at the higher insulin levels. This pattern suggests a change in receptor affinity rather than a change in receptor number, and this point is made clearer by analyzing the Scatchard plots 19 of these data. With this method of analysis, the x-intercept represents the number of insulin receptor sites per cell and, as Figure 3 demonstrates, these intercepts are the same for all groups. Calculations reveal that there are ~30 receptor sites per cell under all conditions. Therefore, the decrease in insulin binding induced by either infusion must be the result of a decrease in receptor affinity, and this is confirmed by plotting the data on an average affinity graph (Figure 4) , as described by De Meyts and Roth. 20 The average affinity (K) is decreased by 38% at levels of receptor occupancy less than 50%, supporting the concept that 5 h of either infusion leads to a decrease in receptor affinity with no change in receptor number.
In seven of the eight subjects who received the hyperglycemic infusion and in five of the six subjects who received the hyperinsulinemic infusion, a clear-cut decrease was observed in insulin binding caused by reduced receptor affinity. One subject (no. 3), who received both infusions, did not exhibit any change in the binding curves.
To be certain these changes were not limited to erythrocyte insulin receptors, insulin binding to isolated monocytes was determined in one subject during a hyperinsulinemic infusion: The results are presented in Figure 5 . After 5 h of the infusion, insulin binding to monocytes was decreased by 37%, and the shapes of these curves are identical to those seen in Figure 2 . Scatchard and average affinity analysis demonstrate a decrease in receptor affinity only (data not shown). The basal insulin and glucose values were 7 /xU/ml and 82 mg/100 ml, respectively, and were 82 ^ll/ml and 79 mg/100 ml at 5 h of the infusion. Erythrocyte insulin binding decreased 39% during the hyperinsulinemic infu- sion in this same subject. Thus, the effects were comparable in both cell types.
To determine if the epinephrine and propranolol in the infusion mixture were responsible for any of the receptor alterations, two subjects who had already demonstrated a decrease in insulin binding in response to the hyperglycemic infusion were given epinephrine (6 ju,g/min) and propranolol (0.08 mg/min) in normal saline, and insulin binding to erythrocytes was measured at 0 and 5 h of this infusion. A small amount of exogenous insulin (10 mU/min) was administered to prevent a fall in basal insulin values. In these studies, basal glucose and insulin levels were 90 mg/100 ml and 10,/xU/ml, respectively, and were 85 mg/100 ml and 16 //U/ml at 5 h. As Figure 6 demonstrates, the infusion of epinephrine and prppranolol in saline for 5 h had no effect on erythrocyte insulin binding. ' .
Insulin-binding studies in vitro.
Thus far, the data show that, after 5 h of either the hyperglycemic or hyperinsulinemic infusion, insulin receptor affinity decreases in vivo. Next, it was of interest to determine whether similar changes could occur in vitro. As seen in Table 1 , no change in insulin binding was seen using cells prepared immediately after 3 h of infusion. On the other harfd, when blood was obtained at 3 h and was incubated as whole blood in vitro at 4° for 2 h, a striking decline was observed in the amount of insulin that bound to subsequently prepared erythrocytes ( Figure 7 ). As can be seen in Figure 7 , the decrease in insulin binding that developed during the 2 h of in vitro incubation was identical to the decline in insulin binding that occurred in vivo between the third and fifth hours of the infusions. Analysis of the complete binding curves demonstrated that this decrease in insulin binding was due to a decrease in receptor affinity, comparable to the in vivo results (Figures 2-4) .
To determine whether this in vitro change in insulin binding was dependent on a plasma factor present during the incubation, blood was obtained at 3 h of the hyperglycemic infusion, plasma was removed from the cell pellet, and the cells were incubated in vitro with buffer at 4° (N = 4). Insulin binding to the erythrocytes prepared at the end of 2 h of incubation in buffer decreased the same as was seen when the in vitro incubation was performed in whole blood (Table  2) . Comparable changes occurred when the in vitro incubation was carried out at 22° or 37°. Furthermore, no changes in insulin binding could be induced when cells prepared in the basal state were incubated for 5 h with plasma obtained at the end of 5 h of infusion previously performed in the same subject. Lastly, in vitro changes in insulin binding were not induced when cells prepared jn the basal state were incubated for 5 h with 20 mM glucose. Thus, it appears that the signal which triggers the change in receptor affinity is generated during the first 3 h of the infusion and can be subsequently expressed either in vitro or in vivo.
To better characterize the time course of the changes in Counterregulatory hormone levels. Table 3 presents the mean (±SE) levels of cortisol and growth hormone at 0 and 5 h of each type of infusion study. Cortisol levels decline slightly during the infusion, and this might be expected on the basis of either normal diurnal variation or the suppressive effects of glucose metabolism. No consistent change in growth hormone levels were observed.
DISCUSSION
Many conditions have been reported in which the binding of insulin to its receptor is altered. 2 ' 3 Although a number of studies have corroborated the concept that insulin may control its receptors-hyperinsulinemia leading to a decrease in receptors, and hypoinsulinemia leading to an increase in 4 -the existing evidence suggests that this process may take several days in man. 6 ' 7 Given the short term dynamics and crucial homeostatic importance of the insulin-insulin receptor-glucose metabolism sequence, it seemed reasonable to suspect that a short term regulatory mechanism for alteration in insulin binding might also exist. In support of this hypothesis, there have been recent reports of acute insulin receptor affinity changes associated with fasting, 5 ' 6 -8 - 21 exercise, 22 and oral glucose ingestion. 9 In the present study, we have demonstrated that an acute phase change in insulin binding occurs in response to 5 h of either a hyperglycemic or hyperinsulinemic intravenous infusion.
The feasibility of investigating rapid changes in insulin binding is contingent on access to a readily available tissue source for serial studies. The erythrocyte provides an ideal tool for such purposes, since sufficient numbers of cells can be prepared from 10 ml of whole blood to perform a complete competition study. Although a physiologic role for insulin receptors in these cells has not been described, these receptors are highly specific for insulin, with binding characteristics comparable to insulin receptors of other tissue's.
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Using this approach, we have found that in vivo exposure to either hyperinsulinemia and euglycemia or hyperglycemia and a minimal change of basal insulin levels leads to a striking decrease in insulin binding. Both Scatchard 19 and average affinity analysis 20 demonstrate that this decrease in insulin binding is caused by a decrease in receptor affinity. The time course of these in vivo changes was such that, when cells were prepared after 3 h of either infusion, no alterations in insulin binding were observed; however, after 5 h of infusion, this effect was fully evident. We do not know whether other changes would have occurred had the infusions been carried out for a longer time. The data in Figure 5 show that these events were not limited to erythrocytes, since identical results were obtained when isolated monocytes were studied, consistent with the possibility that these effects are expressed in other tissues.
The results also show that identical changes can occur in vitro if the cells are removed from the in vivo setting. Thus, when cells were obtained after 3 h of either infusion and then incubated in vitro for an additional 2 h, the same change in receptor affinity that would have occurred between the third and fifth hours in vivo could be demonstrated. This is an intriguing observation which indicates that some process is activated which programs the cell to develop the observed changes in receptor affinity in a time-dependent fashion, independent of maintenance of the in vivo environment. When the temporal sequence of these events was studied more carefully, we found that cells obtained at 2 h of the infusion were partially programmed to develop the decrease in insulin binding, whereas after only 1 h of infusion no changes developed in vitro. Whether this implies incremental activation of these processes in all cells or a gradual recruitment of cells into the fully programmed state is unclear. It should be noted that the apparent time sequence of these events is only semiquantitative, since the time required to prepare cells and to measure insulin binding is not considered. However, this latter interval is the same under all conditions.
Whatever the nature of this triggering process, it is most probable that this signal is intrinsic to the cell itself. Thus, when erythrocytes obtained at 3 h of infusion were incubated in vitro in buffer, the decrease in receptor affinity could still develop fully. This suggests that this process is unrelated to plasma factors, at least after 3 h of in vivo exposure. Furthermore, when cells were obtained at basal conditions and were incubated for 5 h with plasma obtained at the end of 5 h of infusion in the same subject (on the previous day) or buffer containing 20mM glucose, no change in insulin binding was noted. Although a highly labile plasma factor could be missed with this approach, this finding is still most consistent with the idea of an intrinsic cellular signal. On balance, the results support the hypothesis that a signals) is generated during the first 2 or 3 h of the infusion; which, by that time, is intrinsic to the cells; after 2 or 3 h of a latent period, this signal then leads to a decrease in receptor affinity. Since erythrocytes lack nuclei, do not internalize insulin, 23 and contain sparse intracellular metabolic processes, it is difficult to conceive of a mechanism whereby changes in receptor number occur. However, the alterations we observed were in receptor affinity and are most likely mediated through some direct plasma membrane perturbation in response to the infusion or perhaps via some aspect of the glycolytic pathway.
Clearly the mechanisms underlying this regulatory process remain to be elucidated. Although the magnitude of the prevailing plasma insulin level has been previously shown to have a major influence on insulin receptor number, this effect takes a relatively long time in man, 5 " 7 and our data suggest that the plasma insulin concentration is not the primary factor producing these acute phase changes. First, comparable changes in receptor affinity were seen with both infusion protocols despite marked differences in insulin levels. Secondly, in the hyperglycemic protocol, plasma insulin levels increased only modestly and not in all subjects. When these subjects are divided into those whose plasma insulin levels during the infusion were <15 /u,U/ml (N = 3) and those whose insulin levels were >15 juU/ml (N = 5), the decrease in maximal insulin binding was 43% in the former group and 32% in the latter group. Lastly, during the epinephrine, propranolol, and insulin (10 mU/min) infusions (Figure 6 ), which did not lead to changes in receptor affinity, the plasma insulin level at 5 h was 16 ju,U/ml. This is greater than the plasma insulin level at 5 h in the three subjects with the greatest change in receptor affinity during the hyperglycemic infusion. Although these arguments do not eliminate the possibility that the modest increase in plasma insulin levels during the hyperglycemic infusion are critical to the observed changes in receptor affinity, we believe that, on balance, the results make this formulation unlikely. However, further studies will be necessary to completely evaluate this issue.
The evidence also indicates that hyperglycemia per se is not critical to the development of the receptor changes. During the hyperinsulinemic infusions, euglycemia was approximated, and yet the receptor changes were identical to those produced by the hyperglycemic infusion. Furthermore, control studies indicated that 5 h of infusion of epinephrine and propranolol in saline led to no alteration in insulin binding, demonstrating that the epinephrine and propranolol did not induce the observed effects. Lastly, in the hyperinsulinemic infusions, the decrease in insulin binding was not simply a result of the occupancy of receptors in vivo, with subsequent masking of receptors during the in vitro assay, since addition of a large amount of insulin (100 ng/ml) to whole blood did not affect the subsequent determination of insulin binding (data not shown). The reason for this is that the multiple dilutions and washings involved in cell preparation are sufficient to allow all previously bound insulin to dissociate from the cells.
Since plasma glucose or insulin levels per se do not appear to be the primary mediators of these acute phase changes in insulin binding, other factors need to be considered. As one example, growth hormone levels increase in fasting, exercise, and acromegaly, and all these conditions have been associated with an increase in insulin receptor affinity. 25 and is associated with lower growth hormone levels. These in vivo associations are consistent with the possibility that growth hormone may influence insulin receptor affinity. However, a direct effect of growth hormone on insulin binding has not been demonstrated in vitro, 26 and the data in Table 2 show no consistent change in the level of this hormone during the infusion studies. Obviously, the plasma levels of a variety of other hormones and substrates also change in these conditions, but data to implicate such factors are not yet available. Another possibility is that the signal responsible for these changes in receptor affinity is an intracellular product of cellular metabolism. In this event, since erythrocytes use only a few metabolic pathways, some product of glucose catabolism may be operative. With this formulation, however, it should be noted that insulin has not been shown to exert physiologic effects on erythrocyte metabolism.
The relationship between these acute phase changes in receptor affinity and total glucose homeostasis is unclear. Beck-Nielson and Pedersen have reported a diurnal variation in insulin binding to monocytes, with a decrease during the day associated with food ingestion, 27 although others have not confirmed this observation. 28 Additionally, sustained high carbohydrate feedings will lead to depressed insulin receptor affinity. 7 It is possible that some aspect of the fed state may lead to a fall in receptor affinity, whereas fasting has the opposite effect. The data of Muggeo et al. 9 are a possible exception to this line of reasoning. These workers found an increase in binding affinity after an oral glucose load. However, this effect was only noted 5 h after an oral glucose tolerance test; at this time the body is shift-ing from the fed to the fasted state and is recovering from the normal insulin-induced hypoglycemia that commonly occurs between 3 h and 5 h of this procedure.
Since insulin binding falls at 5 h of the infusion, one might expect to see some manifestation of decreased insulin sensitivity at this time. Inspection of the steady state plasma glucose levels at 3 h and 5 h of the infusions gives no support to this prediction. If anything, glucose levels are somewhat lower at 5 h compared with at 3 h (Figure 2 ), suggesting a possible increase in overall insulin effectiveness. Several situations exist in which insulin binding and insulin action can be dissociated (e.g., fasting 8 ' 29 and high carbohydrate feedings 6 ' 25 ) , and the net effect of any given perturbation on insulin action is a result of changes in postreceptor events as well as changes in insulin binding. In this regard, high carbohydrate ingestion leads to increased insulin effectiveness, and the enhanced activity of such postreceptor steps as the glucose transport system and intracellular metabolism have been demonstrated. 25 ' 30 It is possible that 5 h of glucose plus insulin infusions can lead to some augmentation of these processes.
In summary, we have demonstrated that 5 h of either hyperinsulinemia or hyperglycemia will lead to decreased insulin receptor affinity. This decrease in receptor affinity will develop in vivo or in vitro, and, once a cell is programmed to develop these changes, this will be expressed in the absence of any plasma factors. The exact nature of the signal that mediates these effects remains to be elucidated.
